260 related articles for article (PubMed ID: 36296495)
1. Cell Cycle Arrest and Apoptosis-Inducing Ability of Benzimidazole Derivatives: Design, Synthesis, Docking, and Biological Evaluation.
Nazreen S; Almalki ASA; Elbehairi SEI; Shati AA; Alfaifi MY; Elhenawy AA; Alsenani NI; Alfarsi A; Alhadhrami A; Alqurashi EA; Alam MM
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296495
[TBL] [Abstract][Full Text] [Related]
2. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
3. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, Molecular Docking, and Biological Evaluation of Isatin-Based Fused Heterocycles As Epidermal Growth Factor Receptor Inhibitors.
Kumar A; Kumar B; Bhatia R
Assay Drug Dev Technol; 2023 Jul; 21(5):222-233. PubMed ID: 37439798
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors.
Akhtar MJ; Khan AA; Ali Z; Dewangan RP; Rafi M; Hassan MQ; Akhtar MS; Siddiqui AA; Partap S; Pasha S; Yar MS
Bioorg Chem; 2018 Aug; 78():158-169. PubMed ID: 29571113
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
Yang X; Hou Z; Wang D; Mou Y; Guo C
Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
Srour AM; Ahmed NS; Abd El-Karim SS; Anwar MM; El-Hallouty SM
Bioorg Med Chem; 2020 Sep; 28(18):115657. PubMed ID: 32828424
[TBL] [Abstract][Full Text] [Related]
8. New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis,
Yaseen YS; Mahmood AAR; Abbas AH; Shihab WA; Tahtamouni LH
Med Chem; 2023; 19(5):445-459. PubMed ID: 36537605
[TBL] [Abstract][Full Text] [Related]
9. New phthalimide-based derivatives as EGFR-TK inhibitors: Synthesis, biological evaluation, and molecular modeling study.
Mansour NI; El-Sayed SM; El-Gohary NS; Abdel-Aziz NI; El-Subbagh HI; Ghaly MA
Bioorg Chem; 2022 Oct; 127():105966. PubMed ID: 35728294
[TBL] [Abstract][Full Text] [Related]
10. New 1,3,4-oxadiazoles linked with the 1,2,3-triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase.
Mahmoud MA; Mohammed AF; Salem OIA; Gomaa HAM; Youssif BGM
Arch Pharm (Weinheim); 2022 Jun; 355(6):e2200009. PubMed ID: 35195309
[TBL] [Abstract][Full Text] [Related]
11. Novel 5-bromoindole-2-carboxylic Acid Derivatives as EGFR Inhibitors: Synthesis, Docking Study, and Structure Activity Relationship.
Hassan OM; Kubba A; Tahtamouni LH
Anticancer Agents Med Chem; 2023; 23(11):1336-1348. PubMed ID: 36847231
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
Shaheen MA; El-Emam AA; El-Gohary NS
Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
[TBL] [Abstract][Full Text] [Related]
14. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
Raghunath Khedkar N; Sindkhedkar M; Joseph A
Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
[TBL] [Abstract][Full Text] [Related]
15. Azole-hydrazone derivatives: Design, synthesis, in vitro biological evaluation, dual EGFR/HER2 inhibitory activity, cell cycle analysis and molecular docking study as anticancer agents.
Labib MB; Philoppes JN; Lamie PF; Ahmed ER
Bioorg Chem; 2018 Feb; 76():67-80. PubMed ID: 29153588
[TBL] [Abstract][Full Text] [Related]
16. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
17. Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors.
Elbastawesy MAI; Aly AA; Ramadan M; Elshaier YAMM; Youssif BGM; Brown AB; El-Din A Abuo-Rahma G
Bioorg Chem; 2019 Sep; 90():103045. PubMed ID: 31212178
[TBL] [Abstract][Full Text] [Related]
18. Novel 2-Sulfanylquinazolin-4(3
Altharawi A; Alanazi MM; Alossaimi MA; Alanazi AS; Alqahtani SM; Geesi MH; Riadi Y
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513420
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, biological assessment and molecular modeling studies of novel imidazothiazole-thiazolidinone hybrids as potential anticancer and anti-inflammatory agents.
Kamboj P; Anjali ; Imtiyaz K; Rizvi MA; Nath V; Kumar V; Husain A; Amir M
Sci Rep; 2024 Apr; 14(1):8457. PubMed ID: 38605072
[TBL] [Abstract][Full Text] [Related]
20. New 1,3,4-oxadiazole-chalcone/benzimidazole hybrids as potent antiproliferative agents.
Hagar FF; Abbas SH; Abdelhamid D; Gomaa HAM; Youssif BGM; Abdel-Aziz M
Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200357. PubMed ID: 36351754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
